drugset / Trial / NCT04556617
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Timeline
- Start
- 2020-09-21
- Primary completion
- 2022-05-24
- Completion
- 2022-05-24
Outcome
Outcome not reported
Stopped (Business): “study terminated due to business realignment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLX2853 | Unknown | 20 mg | — |
| Subject | PLX2853 | Unknown | 40 mg | — |
| Subject | PLX2853 | Unknown | 80 mg | — |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Olaparib | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |